Cantor Fitzgerald Has Weak Outlook for TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at Cantor Fitzgerald dropped their FY2026 EPS estimates for shares of Travere Therapeutics in a note issued to investors on Friday, October 31st. Cantor Fitzgerald analyst P. Agrawal now expects that the company will post earnings of $0.91 per share for the year, down from their previous forecast of $1.00. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. The company had revenue of $113.15 million during the quarter, compared to analysts’ expectations of $106.09 million. Travere Therapeutics had a negative net margin of 50.64% and a negative return on equity of 717.68%. The firm’s revenue for the quarter was up 162.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.70) EPS.

Several other research firms also recently issued reports on TVTX. Piper Sandler lifted their price objective on Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday. Wells Fargo & Company raised their price target on shares of Travere Therapeutics from $27.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Travere Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Wedbush boosted their target price on shares of Travere Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $38.71.

Travere Therapeutics Trading Down 1.2%

NASDAQ:TVTX opened at $34.13 on Monday. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -16.73 and a beta of 0.83. Travere Therapeutics has a one year low of $12.91 and a one year high of $36.15. The company has a debt-to-equity ratio of 9.50, a quick ratio of 1.98 and a current ratio of 2.00. The business’s 50-day simple moving average is $25.18 and its 200 day simple moving average is $19.68.

Insider Buying and Selling

In related news, insider Elizabeth E. Reed sold 10,000 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the insider directly owned 89,878 shares in the company, valued at $2,246,950. This represents a 10.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter Heerma sold 5,591 shares of the stock in a transaction on Friday, October 31st. The stock was sold at an average price of $35.00, for a total value of $195,685.00. Following the completion of the sale, the insider directly owned 119,071 shares in the company, valued at $4,167,485. This represents a 4.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 156,826 shares of company stock valued at $4,805,240 over the last three months. 4.19% of the stock is owned by company insiders.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Travere Therapeutics during the first quarter valued at approximately $182,000. Polar Asset Management Partners Inc. bought a new position in Travere Therapeutics in the 1st quarter worth approximately $304,000. Northern Trust Corp increased its position in Travere Therapeutics by 7.2% in the 1st quarter. Northern Trust Corp now owns 808,687 shares of the company’s stock valued at $14,492,000 after acquiring an additional 54,292 shares during the period. Assenagon Asset Management S.A. raised its stake in Travere Therapeutics by 166.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,103,075 shares of the company’s stock valued at $16,326,000 after acquiring an additional 689,561 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its position in Travere Therapeutics by 343.7% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 68,000 shares of the company’s stock worth $1,006,000 after acquiring an additional 52,675 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.